SCHEMBL21329645

SCHEMBL21329645

C=Cc1cc(Cl)nc(C2(OC)CCOC2)c1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 14/20 0.34
▸ JAK2 O60674 2/20 0.34
▸ ALOX5 P09917 2/20 0.33
▸ JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21329834 0.87 TYK2 (0.36) TYK2JAK2ALOX5JAK1
SCHEMBL21329843 0.80 TYK2 (0.42) TYK2JAK2ALOX5JAK1
SCHEMBL21329657 0.80 TYK2 (0.38) TYK2JAK2ALOX5JAK1
SCHEMBL21330056 0.80 TYK2 (0.42) TYK2JAK2ALOX5JAK1
SCHEMBL21329839 0.80 TYK2 (0.42) TYK2JAK2ALOX5JAK1
SCHEMBL21329659 0.80 TYK2 (0.38) TYK2JAK2ALOX5JAK1
SCHEMBL21329872 0.80 TYK2 (0.38) TYK2JAK2ALOX5JAK1
SCHEMBL21330053 0.78 ALOX5 (0.36) TYK2JAK2ALOX5JAK1
SCHEMBL21329591 0.77 TYK2 (0.43) TYK2JAK2ALOX5JAK1
SCHEMBL21329936 0.77 TYK2 (0.43) TYK2JAK2ALOX5JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC (US) 2020-08-13 — — US disclosed
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC (US) 2020-08-13 — — US disclosed
WO-2019178079-A9 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-12-12 — — WO disclosed
WO-2019178079-A9 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-12-12 — — WO disclosed
WO-2019178079-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-09-19 — — WO disclosed
WO-2019178079-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-09-19 — — WO disclosed
EP-3539966-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING AbbVie Inc. (US) 2019-09-18 — — EP disclosed
EP-3539966-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING AbbVie Inc. (US) 2019-09-18 — — EP disclosed
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. 2019-09-12 — — US disclosed
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. 2019-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING PTK2B, ABL1, BTK TYK2 36/4885JAK2 8/4885ALOX5 4798/4885
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING PTK2B, ABL1, BTK TYK2 36/4885JAK2 8/4885ALOX5 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback